Company intelligence / Profile preview

Alera Pharma

Undisclosed, Undisclosed, United States

Ownership: Private
Development stage: Other

Overview

Alera Pharma holds IP for neurological drug assets including Psilocin Mucate and is active in Phase 1 and Phase 2 clinical development mainly for chronic cluster headache and refractory anxiety

Therapeutic areas: NeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Collaborations with Lobe Sciences and industry-leading partners (details not disclosed)

Beyond the preview

Go deeper on Alera Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alera Pharma.

Explore the full profile